# Institut de Cancérologie de l'Ouest

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/institut-de-cancerologie-de-l-ouest/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 65.4 |
| Citations | 208,930 |
| City | Angers |
| Country | FR |
| Description | Institut de Cancérologie de l'Ouest is a research organisation in Angers, FR. OpenAlex records 4,404 works and 208,930 citations for it. 914 researchers list it as their most recent affiliation. |
| Homepage | https://www.institut-cancerologie-ouest.com |
| OpenAlex ID | https://openalex.org/I4210106090 |
| Region | Pays de la Loire |
| Researchers | 914 |
| ROR ID | https://ror.org/01m6as704 |
| Type | healthcare |
| Works | 4,404 |

## University papers

Showing 12 of 26.

- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-selective-internal-radiotherapy-with-yttrium-90-resin/)
- [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/)
- [Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034](https://scholariq.org/papers/randomized-phase-ii-trial-of-erlotinib-versus-temozolomide-or-carmustine-in/)
- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)

## University researchers

- [Judith Raimbourg](https://scholariq.org/researchers/judith-raimbourg/)

## University top topics

Showing 8 of 25.

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.